<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-JLQLXVHQ</identifier><date>2010</date><creator>Klančar, Uroš</creator><creator>Kristl, Albin</creator><creator>Legen, Igor</creator><creator>Mrhar, Aleš</creator><relation>documents/doc/J/URN_NBN_SI_doc-JLQLXVHQ_001.htm</relation><relation>documents/doc/J/URN_NBN_SI_doc-JLQLXVHQ_001.pdf</relation><relation>documents/doc/J/URN_NBN_SI_doc-JLQLXVHQ_001.txt</relation><format format_type="issue">3</format><format format_type="volume">61</format><format format_type="type">article</format><format format_type="extent">str. 162-170</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">2829169</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-JLQLXVHQ</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">farmakodinamika</subject><subject language_type_id="slv">metabolizem</subject><subject language_type_id="slv">sproščanje zdravil</subject><title>"In vitro-in vivo" korelacija (IVIVC) za učinkovine v pripravkih s podaljšanim sproščanjem, ki se intenzivno metabolizirajo ali absorbirajo s prenašalci v prebavilih</title><title>In vitro in vivo correlation (IVIVC) for drugs in extended release formulations which are extensively metabolized or absorbed with transporters</title></Record>